A team of Northwestern University scientists spanning disciplines have developed new technology that could lead to the creation of a rapid point-of-care test for HIV infection competitive with traditional lab-based HIV testing in a...
Ethicist Art Caplan discusses progress in gene therapy research and the need for medical professionals and regulators to tolerate appropriate risk. Medscape Business of Medicine
The modified vaccinia Ankara-Bavarian Nordic vaccine, originally approved for smallpox, is safe and well tolerated in at-risk individuals, with one dose offering protection against mpox. Medscape News UK
If the past four decades have taught us anything about HIV, it's to adjust our expectations—despite enormous progress in controlling the virus, no treatment can yet completely eradicate HIV once it has taken hold. But promising results...
A federal judge ordered a Johnson & Johnson unit on Friday to pay the U.S. government $1.64 billion after a jury found it liable in a whistleblower lawsuit for illegally... Reuters Health Information
Gender-affirming hormone therapy (GAHT) is associated with significantly improved HIV outcomes for transgender, nonbinary, and other gender-diverse (trans) people in the U.S., according to a new study published in The Lancet HIV.
A new modeling study published in The Lancet HIV journal highlights the alarming potential impact of significant reductions in international funding for HIV prevention and treatment programs.
The world risks returning to the worst days of the global AIDS pandemic following the sudden halt to US foreign aid funding, the UN's top AIDS official said Monday, warning millions would die.
Two slides presented at last week’s Conference on Retroviruses and Opportunistic Infections (CROI 2025) in San Francisco starkly illustrated the cost of the almost-complete defunding of HIV pre-exposure prophylaxis (PrEP) provision via...
Letermovir, an antiviral drug for cytomegalovirus (CMV), was associated with reduced inflammation, improved CD4/CD8 T-cell ratios and better physical function for people with HIV on effective antiretroviral treatment, according to a...
Over the past week at the Conference on Retroviruses and Opportunistic Infections (CROI 2025) in San Francisco, we have been reminded that Latin America is one of the few global regions where new HIV cases have continued to rise since...
As Gilead Sciences prepares to launch twice-yearly lenacapavir pre-exposure prophylaxis (PrEP) later this year, the company is also developing once-yearly formulations that could make an even greater contribution to ending the HIV epidemic.
Most people with unsuppressed HIV in a large population study in Uganda were already diagnosed but not in clinical care, suggesting that re-engaging people with HIV and ensuring that they are receiving antiretroviral treatment could have...
Two clinical trials presented last week at the Conference on Retroviruses and Opportunistic Infections (CROI 2025) in San Francisco show that a two-drug regimen of doravirine / islatravir is non-inferior to commonly prescribed HIV drug...
Research from an 18-year Spanish cohort presented to the Conference on Retroviruses and Opportunistic Infections (CROI 2025) in San Francisco last week showed a significant reduction in severe non-AIDS events – such as heart attacks and...
Injectable PrEP clearly works at least as well for cisgender women having vaginal sex as it does for people having anal sex. But there remains some uncertainty as to whether the much lower effectiveness of oral PrEP seen in most studies...
While some countries have already shifted to less intensive monitoring requirements for PrEP users, a Dutch study has now provided evidence that it’s OK to test for sexually transmitted infections (STIs) every six months, to have clinic...
Statin treatment may reduce cardiovascular risk in people with HIV not only by lowering cholesterol but also by reducing coronary plaque and inflammation, Professor Steven Grinspoon told the Conference on Retroviruses and Opportunistic...
People with HIV in Uganda do not have a higher prevalence of coronary artery disease compared to people without HIV. Among both groups, the prevalence of coronary artery disease was low compared to populations in Europe and North...
Two studies presented at the Conference on Retroviruses and Opportunistic Infections (CROI 2025) in San Francisco last week found that so far relatively few people with HIV are taking doxyPEP (using the antibiotic doxycycline to prevent...
Evidence for the effectiveness of the alternative formulation of oral PrEP in women was presented at the Conference on Retroviruses and Opportunistic Infections (CROI 2025) in San Francisco last week.
Two new long-acting antiretroviral drugs, VH-184 and VH-499, have demonstrated similar potency to the best available antiretrovirals currently in use in phase 2a proof-of-concept trials, according to findings presented at the Conference...
N6LS, a broadly neutralising antibody from ViiV Healthcare, could potentially be a partner for cabotegravir (Vocabria) in a long-acting HIV treatment regimen, according to results from the EMBRACE study presented at the Conference on...
Two months into the new administration, federal workers and contractors remain off-balance as the Trump administration ramps up its efforts to cancel jobs and programs — even as federal judges declare many of those efforts illegal and/or...
HIV infections are lifelong and can weaken the immune system, causing a patient to be more susceptible to infection and various cancers. Children of mothers with HIV are at risk of developing an HIV infection as it is transmittable...
The Trump administration is weighing elimination of the U.S. Centers for Disease Control and Prevention's (CDC) Division on HIV Prevention, sparking concerns among public health experts.
Universitätsmedizin Berlin has found that a single dose of the Imvanex vaccine provides protection against mpox with 84% effectiveness. For people with HIV, however, a single dose of the vaccine fails to offer sufficient protection. All...
In a study published in AIDS Research and Therapy, Ph.D. candidate Thinh Vu explores the temporal trends in the time from HIV diagnosis to the initiation of antiretroviral therapy (ART) across the Asia-Pacific region. This cohort study,...
Electronic cigarettes use may pose lower cardiovascular risks in people living with HIV compared to tobacco cigarette use, new UCLA-led research shows.
Nearly 85% of the 1.7 million adolescents with HIV live in sub-Saharan Africa, along with half of the nearly 40 million people in the world living with HIV. Although the government in Uganda provides antiretroviral treatment (ART) for...
Hundreds of HIV doctors and researchers have called on the Trump administration to reverse its sweeping aid funding cuts, saying they are "doing catastrophic harm" to the global fight against AIDS.
Two broadly neutralising antibodies, teropavimab and zinlirvimab, might be good partners for lenacapavir (Sunlenca) in a long-acting HIV treatment regimen, according to study results presented yesterday at the Conference on Retroviruses...
The day before the Conference on Retroviruses and Opportunistic Infections (CROI 2025) opened in San Francisco on Sunday, there was a community workshop on HIV cure science, at which Dr Michael Peluso, a local HIV physician and cure...
The global HIV response is suffering serious disruption due to cuts in US government funding, the closure of USAID and a lack of clarity about future financing, Professor Chris Beyrer, Director of the Duke Global Health Institute at Duke...
Two more people appear to be free of HIV after stem cell transplants for cancer treatment, according to a pair of posters presented at the Conference on Retroviruses and Opportunistic Infections (CROI 2025) this week in San Francisco. If...
Nearly one in five children with HIV under the age of one year who experienced an interruption in treatment in 2024 subsequently died, a review of over half a million children receiving HIV treatment through US-funded PEPFAR programmes...
A new study led by Western researchers is the first to identify a factor that could influence how fast the pocket where human immunodeficiency virus (HIV) hides dormant inside of cells shrinks when treated.
Mount Sinai researchers have developed a method to uncover the hidden immune cells that harbor the human immunodeficiency virus (HIV), a discovery that brings medical experts one step closer to a cure for the infection affecting nearly...
Researchers from the HIV Prevention Trials Network (HPTN) have presented results from the HPTN 094 ("INTEGRA") study at the 2025 Conference on Retroviruses and Opportunistic Infections (CROI) in San Francisco.
Adults living with HIV in Malawi are more than twice as likely to also have dementia compared to those without HIV, according to a new study by a team of US and Malawian researchers.
A team of pharmaceutical researchers at biopharma company Gilead Sciences has announced that a reformulation of its HIV prevention drug lenacapavir allows it to persist in the body for up to a year. In their paper published in The Lancet...
A new study published in The Lancet HIV reveals gaps in knowledge surrounding the prevention of HPV-related cancers in people living with HIV and outlines future research priorities.
Enormous progress has been made in tackling the global HIV epidemics over the past two decades. The number of people dying from HIV-related causes has fallen by 51% since 2010; and the number of annual new infections has fallen from 2.1...
Hemorrhage – severe heavy bleeding – and hypertensive disorders like preeclampsia are the leading causes of maternal deaths globally, according to a new study released today by the World Health Organization (WHO).